Delivery Order SPE2DB25D3109-SPE2DB26FP4PG
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,174.80 for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This non-set-aside, competitively awarded contract employs firm fixed pricing and is scheduled for completion by November 17, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $14,183.70 to supply 200-unit vials of Xeomin, a botulinum toxin product used for medical purposes. The contract is a firm fixed-price delivery order with an ultimate completion date of November 21, 2025, and was awarded on October 30, 2025, through a non-set-aside competitive procurement. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $22,349.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The contract was competitively awarded without set-aside designation and is scheduled for completion by October 16, 2025. Performance will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order valued at $8,381.10 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin-based therapeutic product used for medical applications. This non-set-aside, competitively awarded contract is issued under a firm fixed price structure with an ultimate completion date of September 19, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,587.40 for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic applications. This non-set-aside, firm fixed-price delivery order was awarded on October 30, 2025, with an ultimate completion date of November 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $10,057.32 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by October 30, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $6,704.88 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin injection used in medical and therapeutic applications. This firm fixed price delivery order, issued on August 7, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,381.10 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This firm fixed-price contract, awarded on September 26, 2025, with an ultimate completion date of October 20, 2025, represents a non-set-aside competitive award for pharmaceutical supply to federal healthcare systems. The work will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This firm fixed-price delivery order, issued on September 15, 2025, with an ultimate completion date of October 6, 2025, represents a non-set-aside competitive award to the prime contractor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,793.70 delivery order for Xeomin 100 Unit Vials, a botulinum toxin product used for medical purposes. This competitive award, issued on August 25, 2025, carries an ultimate completion date of September 16, 2025, and utilizes firm fixed pricing with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under the company's...
- SPE2DB25D3109Indefinite Delivery Contract
- SPE2DB25D3109-SPE2DB26FP4PGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,117.48 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used in medical and therapeutic applications. This firm fixed price delivery order, awarded on October 30, 2025, with an ultimate completion date of November 21, 2025, represents a single transaction under a broader contract vehicle. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award, indicating it was competitively awarded. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems and other government agencies, including the Defense Health Agency and U.S. Coast Guard. The company's extensive contract portfolio with DLA demonstrates its capability to fulfill diverse pharmaceutical procurement requirements on a global scale across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 10/30/25 |